Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers

Said A. Khelwatty; Sharadah Essapen; Alan M. Seddon; Zhen Fan; Helmout Modjtahedi

doi:10.1038/bjc.2015.319

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers

Said A. Khelwatty, Sharadah Essapen, Alan M. Seddon, Zhen Fan, Helmout Modjtahedi

Research output: Contribution to journal › Article › peer-review

Abstract

Our results provide a novel mechanistic insight into the development of acquired resistance to EGFR antibody-based therapy in colorectal cancer cells and justify further investigations on the therapeutic benefits of pan-HER family inhibitors in the treatment of colorectal cancer patients once acquired resistance to EGFR antibody-based therapy is developed.

Original language	English
Pages (from-to)	1010-1019
Journal	British Journal of Cancer
Volume	113
Issue number	7
Early online date	15 Sept 2015
DOIs	https://doi.org/10.1038/bjc.2015.319
Publication status	Published - 29 Sept 2015

Bibliographical note

Note: This work was supported by a grant from Better Research Into Gastrointestinal Cancer Health and Treatment (BRIGHT), UK.

Keywords

Cancer studies

Access to Document

10.1038/bjc.2015.319

Khelwatty-S-32508Final published version, 1.42 MBLicence: CC BY-NC-SA

http://dx.doi.org/10.1038/bjc.2015.319

Cite this

@article{f5a48e65ebd845ecb42af8c498b5b1dd,

title = "Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers",

abstract = "Our results provide a novel mechanistic insight into the development of acquired resistance to EGFR antibody-based therapy in colorectal cancer cells and justify further investigations on the therapeutic benefits of pan-HER family inhibitors in the treatment of colorectal cancer patients once acquired resistance to EGFR antibody-based therapy is developed.",

keywords = "Cancer studies",

author = "Khelwatty, \{Said A.\} and Sharadah Essapen and Seddon, \{Alan M.\} and Zhen Fan and Helmout Modjtahedi",

note = "Note: This work was supported by a grant from Better Research Into Gastrointestinal Cancer Health and Treatment (BRIGHT), UK.",

year = "2015",

month = sep,

day = "29",

doi = "10.1038/bjc.2015.319",

language = "English",

volume = "113",

pages = "1010--1019",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "7",

}

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. / Khelwatty, Said A.; Essapen, Sharadah; Seddon, Alan M. et al.
In: British Journal of Cancer, Vol. 113, No. 7, 29.09.2015, p. 1010-1019.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers

AU - Khelwatty, Said A.

AU - Essapen, Sharadah

AU - Seddon, Alan M.

AU - Fan, Zhen

AU - Modjtahedi, Helmout

N1 - Note: This work was supported by a grant from Better Research Into Gastrointestinal Cancer Health and Treatment (BRIGHT), UK.

PY - 2015/9/29

Y1 - 2015/9/29

N2 - Our results provide a novel mechanistic insight into the development of acquired resistance to EGFR antibody-based therapy in colorectal cancer cells and justify further investigations on the therapeutic benefits of pan-HER family inhibitors in the treatment of colorectal cancer patients once acquired resistance to EGFR antibody-based therapy is developed.

AB - Our results provide a novel mechanistic insight into the development of acquired resistance to EGFR antibody-based therapy in colorectal cancer cells and justify further investigations on the therapeutic benefits of pan-HER family inhibitors in the treatment of colorectal cancer patients once acquired resistance to EGFR antibody-based therapy is developed.

KW - Cancer studies

UR - http://www.ncbi.nlm.nih.gov/pubmed/26372697

U2 - 10.1038/bjc.2015.319

DO - 10.1038/bjc.2015.319

M3 - Article

C2 - 26372697

SN - 0007-0920

VL - 113

SP - 1010

EP - 1019

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 7

ER -

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this